The 2026 kratom map — where each state stands

Tap any state for its statute, dates, and sources.

U.S. kratom status · July 2026

Tennessee’s ban took effect July 1, 2026

U.S. kratom legal status by state, July 2026 ME WI VT NH WA ID MT ND MN IL MI NY MA RI OR NV WY SD IA IN OH PA NJ CT CA UT CO NE MO KY WV VA AZ NM KS AR TN NC OK LA MS AL SC TX GA FL Tennessee — ban in effect July 1, 2026 · home state
  • Fully banned · 8 states Possession, sale, and manufacture are criminal offenses.
  • KCPA regulated-legal · 30+ states Legal for adults 21+ with labeling, testing, and 7-OH caps.
  • Pending 2026 ban bill · 4 shown Legislation introduced or passed one chamber; not yet law.
  • Reversed a ban · Rhode Island First state to move from prohibition back to regulated-legal.
  • Other / no specific statute Kratom legal but without a KCPA framework in place.

The map is a quick reference. Some KCPA states also have active repeal bills (Georgia and South Carolina appear as both regulated and pending), and enforcement strictness varies. Every state, statute, effective date, and source is listed in the grouped cards below.

Fully banned

Where kratom is illegal

8 states

As of July 2026, eight U.S. states treat kratom as a controlled substance or otherwise prohibited product, including Tennessee as of July 1, 2026. Possession, sale, and manufacture are criminal offenses; the specific penalties and statutory mechanisms vary by state.

Home state · ban in effect

Tennessee

Effective Jul 1, 2026

HB1649/SB1656, called “Matthew Davenport’s Law,” passed both chambers on April 16, 2026 with a Senate vote of 23-3. Gov. Bill Lee signed it into law on May 7, 2026 (Public Chapter 950); it took effect July 1, 2026. Penalties are Class A misdemeanor for knowing possession, Class C felony for manufacture, delivery, or sale, and Class B felony for sale to a minor. Tennessee is now the eighth fully-banning state. The introduced version (HB1647/SB1655) carried a harsher Class D/Class B/Class A felony structure; the passed substitute reduced possession from felony to misdemeanor before clearing the legislature. See our Tennessee kratom ban law article.

LegiScan HB1649 LegiScan SB1656 LegiScan HB1647 WSMV News

Connecticut

Newest · Mar 25, 2026

Connecticut is the most recent addition to the banned-state list, with prohibition taking effect March 25, 2026. The statute follows a Schedule I classification model, criminalizing possession, sale, and manufacture of kratom and its alkaloid derivatives. Retailers were given a compliance window to remove inventory before the effective date, and state enforcement has ramped up product seizures since.

CT DCP · passage CT DCP · compliance window

Louisiana

Effective Aug 2025

Louisiana enacted a full kratom ban in August 2025 via Senate Bill 154 (Act 41), making it the sixth fully-banning state at the time. The statute criminalizes possession, sale, and manufacture of kratom and its alkaloid derivatives. Post-effective-date enforcement has included retailer inspections and product-seizure authority; penalties escalate for repeat violations under the state controlled-substance statute.

LA Dept of Revenue LA Legislature · SB154

Alabama

Schedule I since 2016

Alabama was the first state to classify mitragynine and 7-hydroxymitragynine as Schedule I controlled substances, under Alabama Code § 20-2-23, in place since 2016. Knowing possession of any quantity is a Class C felony; manufacture, delivery, or sale rises to a Class B felony. On March 25, 2026, the Alabama Attorney General issued a statewide cease-and-desist wave targeting branded kratom and 7-OH products. See our companion article on Alabama kratom law in 2026.

Alabama Code § 20-2-23 Alabama AG

Arkansas

Schedule I since 2016

Arkansas followed Alabama’s lead in 2016, adding mitragynine and 7-hydroxymitragynine to the state’s Schedule I list. Penalties follow Arkansas’s general controlled-substance statute: possession is a felony, and trafficking carries multi-year prison exposure depending on quantity and prior record. Arkansas has not revisited its classification despite lobbying by kratom consumer groups.

Arkansas Schedule I

Indiana

Synthetic-drug statute

Indiana classifies kratom alkaloids under its synthetic drug statute (IC 35-31.5-2-321) rather than a controlled-substance list, criminalizing possession, sale, and manufacture with penalty tiers comparable to controlled-substance offenses. The practical effect for consumers is the same: possession is a criminal offense and commercial retail is prohibited.

Indiana Code IC 35-31.5-2-321

Vermont

Schedule I

Vermont placed kratom on its Schedule I controlled-substance list several years ago. Possession and sale are criminal offenses. Vermont treats mitragynine and 7-hydroxymitragynine as a single regulated category rather than distinguishing natural whole-leaf kratom from concentrated 7-OH products.

Vermont Legislature

Wisconsin

Schedule I

Wisconsin treats kratom alkaloids as Schedule I controlled substances under Wisconsin Statute 961.14. Possession and distribution are criminal offenses. Wisconsin has not adopted a KCPA-style regulatory alternative despite proposals to reclassify or exempt specific product categories.

Wisconsin Statute 961.14
Reversed a ban

Rhode Island — the first reversal

1 state

Rhode Island had banned kratom since 2017 under a Department of Health action that placed mitragynine and 7-hydroxymitragynine on the state’s prohibited-substance list. That ban was reversed effective April 1, 2026 — the first time any U.S. state has moved a controlled substance back to regulated-legal status after a prohibition.

Rhode Island

Reversed Apr 1, 2026

The reversal came under the Rhode Island Kratom Act (R.I. Gen. Laws Ch. 21-28.12), which follows the Kratom Consumer Protection Act model: kratom is legal for adults aged 21 and older, subject to labeling, third-party laboratory testing, limits on 7-OH concentration, and a prohibition on synthetic alkaloid additives. Advocates argued that a full ban pushed Rhode Island consumers toward unregulated out-of-state and online vendors, increased exposure to adulterated and mislabeled products, and did not reduce kratom dependence. Whether other banned states revisit their prohibitions in response remains an open question; for now, Rhode Island is the single data point in that direction.

R.I. Gen. Laws Ch. 21-28.12
Regulated-legal

The Kratom Consumer Protection Act framework

30+ states

More than thirty U.S. states regulate kratom under some version of the Kratom Consumer Protection Act. The core of a KCPA-style framework is a shift from “unregulated supplement” treatment to “age-restricted, labeled, tested consumer product.” States vary substantially in how strictly they enforce their rules. Key provisions typically include:

Age

Minimum purchase age 21 Retailers must verify age before sale; selling to minors carries escalating fines and license consequences.

Labeling

Full product labeling Mitragynine and 7-hydroxymitragynine content, serving size, batch/lot ID, expiration date, and a visible 21-plus warning. Some states also require habit-forming and FDA-non-evaluation statements.

Potency

7-OH concentration cap Most KCPA states cap 7-hydroxymitragynine at 2 percent of total alkaloid content; some add absolute-milligram caps.

Purity

No synthetic alkaloids Manufacturers cannot chemically modify kratom alkaloids or spike products with synthesized mitragynine or 7-OH isolates.

Testing

Third-party lab testing Products tested for alkaloid content, heavy metals (lead, arsenic, cadmium, mercury), pesticides, and microbial contaminants; Certificates of Analysis on request.

Registration

Processor registration Stricter states, including Georgia under HB757, require processors to register products annually and attest to FDA-facility manufacturing.

Representative KCPA-adopting states:

  • Arizona
  • Colorado
  • Georgia
  • Kentucky
  • Maryland
  • Nebraska
  • Nevada
  • New York (2026)
  • Oklahoma
  • Oregon
  • Rhode Island (Apr 1, 2026)
  • South Dakota
  • Texas
  • Utah
  • Virginia

In practical terms, a kratom consumer in Arizona, Georgia, or Utah encounters products at retail that are age-verified, behind-counter, and labeled to a common standard. Enforcement of violations is civil and retailer-focused rather than consumer-focused, so possession by a 21-plus adult is not a criminal matter. Thirteen states have explicit labeling-rule requirements; about thirty have some form of regulation, though strictness and enforcement posture vary widely.

Pending 2026

Bills that could change the map

9 states with active bills

Several states have active 2026 legislation that would move them between categories. The list below reflects bills that had cleared at least one legislative chamber or formal committee action as of July 2026. Whether they pass is uncertain; Tennessee’s April 2026 passage suggests ban legislation has more momentum right now than it has had in several years.

Georgia

HB968 · proposed Schedule I

HB968 would reclassify mitragynine and 7-hydroxymitragynine as Schedule I and repeal portions of the existing 2019 Kratom Consumer Protection Act (as amended by HB181 in 2024 and HB757 later). As of July 2026, HB968 has not cleared either chamber. See our Georgia kratom law article.

South Carolina

H.4636 / H.4641 / H.4648 · repeal KCPA

South Carolina passed a Kratom Consumer Protection Act in 2025. Three 2026 bills — H.4636, H.4641, and H.4648 — would repeal the 2025 KCPA and reclassify kratom alkaloids as controlled substances. The bills are in committee as of April 2026. South Carolina would become the fourth state since late 2025 to move from regulated-legal to banned if any advances.

Washington

SB 6287 regulate · SB 6196 95% tax

Two competing bills on different philosophies. SB 6287 would establish a KCPA framework (age-21, labeling, testing), moving Washington into the regulated-legal category. SB 6196 would impose a 95 percent excise tax, which industry observers note would be effectively prohibitive for retail sales. Both were active as of April 2026.

Michigan

House-passed · Senate pending

The Michigan House passed a kratom ban bill on March 18, 2026. It is pending Senate consideration and, if enacted, would move Michigan into the fully-banned category. Michigan’s approach follows a Schedule I model similar to Alabama and Arkansas.

Introduced in five more states

Not yet advanced

Kratom ban bills were introduced in the 2026 session in Illinois, Kansas, West Virginia, Wyoming, and Maryland. None had advanced to a floor vote as of April 24, 2026. State-level ban bills frequently recur session after session, so introduction alone does not predict passage, but the breadth reflects the national momentum toward tighter kratom regulation.

Enacted 2026

Tennessee — enacted this year

Public Chapter 950

Tennessee moved from pending to enacted in 2026 and is now counted among the eight fully-banning states above. HB1649/SB1656 (“Matthew Davenport’s Law”) passed both chambers April 16, 2026 (Senate 23-3), was signed May 7, 2026 as Public Chapter 950, and took effect July 1, 2026 — Class A misdemeanor for knowing possession, Class C felony for manufacture/delivery/sale, Class B felony for sale to a minor. The full breakdown, penalties, and the harsher introduced HB1647 version are in the Tennessee card above and in our Tennessee kratom ban law article.

Kratom legislation can shift during a session. This is factual reporting on U.S. kratom law as of July 2026, not legal advice. If you have a specific legal question about your state or a cross-border scenario, consult an attorney licensed in the relevant jurisdiction. Whatever a state decides, buprenorphine-based treatment for kratom or 7-OH dependence is legal in every U.S. state — the sections below cover what any state’s status means for treatment access.

Federal status — kratom unscheduled, 7-OH scheduling pending

At the federal level, kratom itself remains unscheduled under the Controlled Substances Act. The DEA did not follow through on a proposed temporary scheduling of mitragynine and 7-hydroxymitragynine that was floated and then withdrawn in 2016. In January 22, 2025, the DEA formally designated both alkaloids as “Drugs of Concern” — an administrative label signaling potential for abuse without scheduling the substances outright.

The federal picture shifted meaningfully on July 29, 2025, when the FDA formally recommended to the DEA that concentrated 7-hydroxymitragynine products be scheduled as Schedule I under the Controlled Substances Act. The recommendation was narrow: it targeted concentrated 7-OH products specifically — tablets, gummies, drink mixes, and shots with elevated 7-OH concentrations — rather than natural whole-leaf kratom. The same week, the FDA issued warning letters to seven 7-OH manufacturers. The DEA is reviewing the recommendation through its standard rulemaking process, which requires a public-comment period before any final scheduling action. Federal scheduling decisions typically take months to years, and the DEA had not published a proposed rule for 7-OH as of July 2026.

If concentrated 7-OH is federally scheduled, it becomes illegal to manufacture, sell, or possess nationwide — regardless of any individual state’s position. Natural whole-leaf kratom would remain unscheduled unless separately addressed. Our companion explainer on 7-OH versus whole-leaf kratom covers the pharmacology and regulatory distinction in more depth, and our Is 7-OH banned yet? 2026 status tracker follows the federal scheduling timeline.

What any state’s status means for treatment access

If you or someone you care about is dependent on kratom or 7-OH, the legal status of kratom in your state does not affect whether treatment is available, effective, or covered by insurance. It only affects supply.

In a banned state?

Buprenorphine-based treatment for kratom or 7-OH dependence is legal in every U.S. state, and patients regularly cross state lines for outpatient care. Your home state’s kratom law doesn’t change whether you can start treatment or whether your insurance covers it.

Book AppointmentCall 423-498-2000

Buprenorphine-based MAT works for kratom dependence regardless of state law

Kratom’s primary active alkaloids, mitragynine and 7-hydroxymitragynine, act on the same mu-opioid receptors that fentanyl, heroin, and prescription opioids act on. Although kratom is not itself a classical opioid, the receptor activity means that the same medication-assisted treatment protocol used for opioid use disorder is clinically effective for kratom dependence. Buprenorphine, the active medication in Suboxone, Sublocade, and Brixadi, is a partial opioid agonist that relieves kratom withdrawal, suppresses craving, and provides a stable transition off kratom products over weeks rather than days. These medications are legal and available in every U.S. state because they are FDA-approved with a federal indication for opioid use disorder.

Cross-state outpatient MAT if your home state has banned kratom

If you live in a state where kratom is banned and you are dependent, you can receive outpatient MAT in a neighboring state without any legal issue. Buprenorphine prescribing is governed by federal law and does not require residency in the prescribing state. Insurance coverage generally follows the patient rather than the provider location, with in-network status varying by carrier. In our own geography, Alabama residents from Jackson County routinely access Restoration Recovery’s Chattanooga clinic for outpatient MAT because Chattanooga is the nearest clinic and buprenorphine treatment is legal in every state regardless of local kratom law. Patients in other regional patterns have similar options; the clinical and legal picture supports cross-border treatment access.

42 CFR Part 2 confidentiality regardless of state

Federal confidentiality protections under 42 CFR Part 2 apply to addiction treatment records regardless of the state in which care is delivered. This is a stricter standard than HIPAA and is explicitly designed to prevent disclosure of substance-use-disorder treatment to law enforcement, employers, or insurers without patient consent. Seeking treatment for kratom or 7-OH dependence does not generate a criminal record, a disclosure to kratom-law enforcement, or a public record that could affect employment, housing, or custody.

Common questions about kratom law by state

Which U.S. states have fully banned kratom as of July 2026?

Eight U.S. states fully ban kratom as of July 2026: Alabama, Arkansas, Indiana, Louisiana, Vermont, Wisconsin, Connecticut, and Tennessee. Possession, sale, and manufacture are criminal offenses in those states, with penalties ranging from misdemeanor to felony. Tennessee became the eighth banning state on July 1, 2026; Gov. Lee signed HB1649/SB1656 into law on May 7, 2026 (Public Chapter 950).

Is Rhode Island the first state to reverse a kratom ban?

Yes. Rhode Island had banned kratom since 2017 but reversed the ban effective April 1, 2026, making it the first U.S. state to reverse a prohibition. The new regulatory framework allows kratom sales to adults aged 21 and older with labeling, testing, and product-safety requirements modeled on the Kratom Consumer Protection Act used in other regulated states. The reversal was driven by advocacy arguments that a ban pushed consumers to unregulated sources and created patchwork enforcement problems without reducing dependence.

What is the Kratom Consumer Protection Act (KCPA)?

The Kratom Consumer Protection Act is a model regulatory framework that more than thirty U.S. states have adopted in some form. Core provisions typically include: a minimum purchase age of 21, mandatory product labeling with mitragynine and 7-hydroxymitragynine content, third-party laboratory testing for contaminants, caps on 7-OH concentration (commonly at 2 percent of total alkaloids), a prohibition on synthetic alkaloid additives, and penalties for retailers who sell to minors or mislabel products. States vary in how strictly they enforce KCPA provisions, what penalty structures they impose, and whether retail restrictions include behind-counter display requirements.

Which states have pending kratom ban bills in 2026?

Tennessee’s ban (HB1649/SB1656, signed into law May 7, 2026, Public Chapter 950) took effect July 1, 2026 and is no longer pending. Active 2026 kratom ban legislation still pending elsewhere includes Georgia (HB968, which would repeal the 2019 Kratom Consumer Protection Act and classify mitragynine and 7-OH as Schedule I), South Carolina (H.4636, H.4641, H.4648 would repeal South Carolina’s 2025 KCPA and ban kratom), Washington (SB 6287 regulation approach and SB 6196 proposing a 95 percent excise tax), Michigan (House passed a ban March 18, 2026; Senate consideration pending), and introduced ban bills in Illinois, Kansas, West Virginia, Wyoming, and Maryland.

If I live in a banned-kratom state and am dependent, can I get treatment elsewhere?

Yes. Buprenorphine-based medication-assisted treatment (Suboxone, Sublocade, Brixadi) is legal in every U.S. state because it uses FDA-approved medications with a federal indication for opioid use disorder. Patients in banned-kratom states routinely cross state lines to receive outpatient MAT care in neighboring states. The legal status of kratom in your home state does not affect your ability to receive buprenorphine-based treatment or your insurance’s obligation to cover it. Restoration Recovery serves patients from across Tennessee, Georgia, and Alabama; other states have similar cross-border treatment access.

Where to check current state status

Kratom legislation can shift during a legislative session. For the most current state-level bill status, LegiScan and BillTrack50 publish up-to-date committee actions, floor votes, and signing actions for every state. State legislature websites (typically [state].gov or legis.[state].gov) publish full bill text and voting records. The American Kratom Association maintains a state-by-state status tracker and is a primary source for advocacy-side tracking of active bills. For the federal picture, DEA and FDA press releases and notices in the Federal Register are authoritative. We update this article and our Tennessee, Georgia, and Alabama state pages as bill status changes meaningfully.

This article is published for patient information only. It is not legal advice. If you have a specific legal question about your state or a potential cross-border scenario, consult an attorney licensed in the relevant jurisdiction.

If you are ready to stop using kratom or 7-OH

Whatever your state does with kratom legislation this year, the clinical reality is stable. Buprenorphine-based MAT works for kratom and 7-OH dependence, same-week appointments are available at our Chattanooga, Cleveland, Soddy-Daisy, and Ringgold locations, and most insurance plans cover treatment. Call 423-498-2000 or book a callback when you are ready. If you are outside our service area and looking for outpatient MAT, the same treatment protocols are available through any addiction clinic that prescribes buprenorphine.

Related reading

References

Primary legal and regulatory sources cited in this state-by-state tracker.

  1. U.S. Drug Enforcement Administration, Diversion Control Division. “Kratom (Mitragyna speciosa Korth) — Drugs and Chemicals of Concern” (designation January 22, 2025). [DEA]
  2. U.S. Food and Drug Administration. “FDA Takes Steps to Restrict 7-OH Opioid Products Threatening American Consumers” (July 29, 2025). [FDA]
  3. U.S. Food and Drug Administration. “FDA Issues Warning Letters to Firms Marketing Products Containing 7-Hydroxymitragynine” (July 15, 2025). [FDA]
  4. Code of Alabama. § 20-2-23 (Schedule I; mitragynine and 7-hydroxymitragynine). [State AG / Code]
  5. Indiana Code § 35-31.5-2-321 (synthetic drug, including mitragynine and 7-OH). [State Code]
  6. Louisiana Department of Revenue. “New Penalties for Kratom in Effect Aug. 1” (2025). [State]
  7. Louisiana Legislature. Senate Bill 154 (Act 41), 2025 Regular Session (enrolled). [LA Legislature]
  8. Wisconsin Statute 961.14 (Schedule I controlled substances). [State Code]
  9. Connecticut Department of Consumer Protection. “DCP Applauds Passage of Controlled Substance Drug Schedule Updates” (effective March 25, 2026). [State]
  10. Connecticut Department of Consumer Protection. “Kratom Update October 2025” (compliance window guidance). [State]
  11. General Laws of Rhode Island, Title 21, Chapter 21-28.12 — The Rhode Island Kratom Act (effective April 1, 2026). [State Code]
  12. Tennessee General Assembly. HB1649 / SB1656 (“Matthew Davenport’s Law”), signed into law May 7, 2026 (Public Chapter 950). [LegiScan HB1649] / [LegiScan SB1656]
  13. Tennessee General Assembly. HB1647 (introduced version, replaced by HB1649). [LegiScan]
  14. WSMV4 News, Nashville. “Tennessee kratom ban bill heads to Gov. Bill Lee’s desk” (April 17, 2026). [News]
  15. Georgia General Assembly. HB181 (2019 KCPA), HB757 (processor registration), HB968 (2026 ban proposal). [LegiScan HB181] / [LegiScan HB757] / [LegiScan HB968]
  16. South Carolina Legislature. H.4636, H.4641, H.4648 (2026 session). [LegiScan H.4636]
  17. Washington State Legislature. SB 6287 (KCPA), SB 6196 (95% excise tax). [LegiScan SB 6287] / [LegiScan SB 6196]
  18. Centers for Disease Control and Prevention. “Increases in Kratom-Related Reports to Poison Centers — National Poison Data System, United States, 2015–2025.” MMWR 2026;75(11). [CDC MMWR]